Oral Voclosporin: Novel Calcineurin Inhibitor for Treatment of Noninfectious Uveitis

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2011 Oct 4

PMID 21966207

Citations 4

Authors

Martin Roesel

Christoph Tappeiner

Arnd Heiligenhaus

Carsten Heinz

Affiliations

Soon will be listed here.

Abstract

Voclosporin, a novel immunomodulatory drug inhibiting the calcineurin enzyme, was developed to prevent organ graft rejection and to treat autoimmune diseases. The chemical structure of voclosporin is similar to that of cyclosporine A, with a difference in one amino acid, leading to superior calcineurin inhibition and less variability in plasma concentration. Compared with placebo, voclosporin may significantly reduce inflammation and prevent recurrences of inflammation in patients with noninfectious uveitis. Future studies have to show if these advantages are accompanied by greater clinical efficacy and fewer side effects compared with the classic calcineurin inhibitors.

Citing Articles

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis.

Kale A, Shelke V, Lei Y, Gaikwad A, Anders H Cells. 2023; 12(20).

PMID: 37887284 PMC: 10605893. DOI: 10.3390/cells12202440.

The Conundrum of Clinical Trials for the Uveitides: Appropriate Outcome Measures for One Treatment Used in Several Diseases.

Jabs D, Berkenstock M, Altaweel M, Holbrook J, Sugar E Epidemiol Rev. 2022; 44(1):2-16.

PMID: 35442407 PMC: 10362938. DOI: 10.1093/epirev/mxac001.

Pharmacotherapy for uveitis: current management and emerging therapy.

Barry R, Nguyen Q, Lee R, Murray P, Denniston A Clin Ophthalmol. 2014; 8:1891-911.

PMID: 25284976 PMC: 4181632. DOI: 10.2147/OPTH.S47778.

Voclosporin as a treatment for noninfectious uveitis.

Schultz C Ophthalmol Eye Dis. 2013; 5:5-10.

PMID: 23700374 PMC: 3653814. DOI: 10.4137/OED.S7995.

References

Birsan T, Dambrin C, Freitag D, Yatscoff R, Morris R . The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int. 2005; 17(12):767-71. DOI: 10.1007/s00147-004-0799-z. View

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

Daniel E, Thorne J, Newcomb C, Pujari S, Kacmaz R, Levy-Clarke G . Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149(3):423-32.e1-2. PMC: 2826576. DOI: 10.1016/j.ajo.2009.09.026. View

Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde C, Searles G . Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008; 371(9621):1337-42. DOI: 10.1016/S0140-6736(08)60593-0. View

Kuglstatter A, Mueller F, Kusznir E, Gsell B, Stihle M, Thoma R . Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 2):119-23. PMC: 3045272. DOI: 10.1107/S0907444910051905. View

Ali A, Rosenbaum J . Use of methotrexate in patients with uveitis. Clin Exp Rheumatol. 2010; 28(5 Suppl 61):S145-50. View

Kempen J, Gangaputra S, Daniel E, Levy-Clarke G, Nussenblatt R, Rosenbaum J . Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008; 146(6):802-12.e1. PMC: 2614443. DOI: 10.1016/j.ajo.2008.04.035. View

Lane L, Tamesis R, Rodriguez A, Christen W, Akova Y, Messmer E . Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology. 1995; 102(10):1530-5. DOI: 10.1016/s0161-6420(95)30835-4. View

Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R . A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2006; 54(3):472-8. DOI: 10.1016/j.jaad.2005.10.061. View

10.

Gupta A, Langley R, Lynde C, Barber K, Gulliver W, Lauzon G . ISA247: quality of life results from a phase II, randomized, placebo-controlled study. J Cutan Med Surg. 2009; 12(6):268-75. DOI: 10.2310/7750.2008.07060. View

11.

Taylor A . A review of the influence of aqueous humor on immunity. Ocul Immunol Inflamm. 2004; 11(4):231-41. DOI: 10.1076/ocii.11.4.231.18269. View

12.

Handy R, Trepanier D, Scott G, Foster R, Freitag D . Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 874(1-2):57-63. DOI: 10.1016/j.jchromb.2008.08.023. View

13.

Pleyer U, Mackensen F, Winterhalter S, Stubiger N . [Anti-TNF-α treatment for uveitis. Analysis of the current situation]. Ophthalmologe. 2010; 108(1):13-20. DOI: 10.1007/s00347-010-2256-y. View

14.

Zierhut M, Baatz H, Coupland S, Deuter C, Heiligenhaus A, Heinz C . [Uveitis and the aging]. Ophthalmologe. 2006; 103(9):765-72. DOI: 10.1007/s00347-006-1409-5. View

15.

Suttorp-Schulten M, Rothova A . The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996; 80(9):844-8. PMC: 505625. DOI: 10.1136/bjo.80.9.844. View

16.

Nussenblatt R . The natural history of uveitis. Int Ophthalmol. 1990; 14(5-6):303-8. DOI: 10.1007/BF00163549. View

17.

Mello P, Roma A, Moraes Junior H . [Analysis of the life quality of infectious and non-infectious patients with uveitis using the NEI-VFQ-25 questionnaire]. Arq Bras Oftalmol. 2009; 71(6):847-54. DOI: 10.1590/s0004-27492008000600016. View

18.

Nussenblatt R . Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci. 1991; 32(13):3131-41. View

19.

Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R . Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study. Eur J Dermatol. 2011; 21(1):89-94. DOI: 10.1684/ejd.2010.1185. View

20.

Schiffman R, Jacobsen G, Whitcup S . Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001; 119(6):841-9. DOI: 10.1001/archopht.119.6.841. View